Derivatives of 3,3-diphenylpropylamines
The invention concerns novel derivatives of 3,3-diphenyl-propylamines, methods for their preparation, pharmaceutical compositions containing the novel compounds, and the use of the compounds for preparing drugs. More particularly, the invention relates to novel prodrugs of antimuscarinic agents with superior pharmacokinetic properties compared to existing drugs such as oxybutynin and tolterodine, methods for their preparation, pharmaceutical compositions containing them, a method of using said compounds and compositions for the treatment of urinary incontinence, gastrointestinal hyperactivity (irritable bowel syndrome) and other smooth muscle contractile conditions.
1. 3,3-Diphenylpropylamines of the formula
where:
R 1 is hydrogen and R 2 is C 1 -C 6 alkylcarbonyl; or
R 1 is C 1 -C 6 alkylcarbonyl and R 2 is hydrogen; and
X is a tertiary amino group of formula
where R 8 and R 9 are each independently C 1 -C 8 alkyl and together comprise at least three carbon atoms;
their salts with physiologically acceptable acids, their free bases and, when the 3,3-Diphenylpropylamines are in the form of optical isomers, the racemic mixture and the individual enantiomers.
2. The 3,3-Diphenylpropylamines of claim 1 where R 8 and R 9 are each independently C 1 -C 6 alkyl.
3. The 3,3-Diphenylpropylamines of claim 1 where X is selected from the group consisting of:
4. The 3,3-Diphenylpropylamines of claim 1 where R 1 is hydrogen and R 2 is C 1 -C 6 alkylcarbonyl.
5. The 3,3-Diphenylpropylamines of claim 1 where R 1 is C 1 -C 6 alkylcarbonyl and R 2 is hydrogen.
6. A method of treating urinary incontinence in a patient in need thereof, the method comprising administering to the patient an effective amount of a 3,3-Diphenylpropylamine of the formula
where:
R 1 is hydrogen and R 2 is C 1 -C 6 alkylcarbonyl; or
R 1 is C 1 -C 6 alkylcarbonyl and R 2 is hydrogen; and
X is a tertiary amino group of formula
where R 8 and R 9 are each independently C 1 -C 8 alkyl and together comprise at least three carbon atoms;
or its salt with a physiologically acceptable acid, its free base or, when the 3,3-Diphenylpropylamine is in the form of optical isomers, the racemic mixture and the individual enantiomers.
7. The method of claim 6 where R 8 and R 9 are each independently C 1 -C 6 alkyl.
8. The method of claim 6 where X is selected from the group consisting of:
9. The method of claim 6 where R 1 is hydrogen and R 2 is C 1 -C 6 alkylcarbonyl.
10. The method of claim 6 where R 1 is C 1 -C 6 alkylcarbonyl and R 2 is hydrogen.
11. The method of claim 6 , where the 3,3-Diphenylpropylamine is administered to the patient in the form of a pharmaceutical composition comprising a pharmaceutically acceptable carrier.
12. A pharmaceutical composition comprising an effective amount of a 3,3-Diphenylpropylamine according to any one of claims 1 - 5 and a pharmaceutically acceptable carrier.